Erydel   Report issue

For profit Phase 3
Founded: San Giovanni Italy (2007)
Status: Acquired by Quince Therapeutics (2023)

Organization Overview

First Clinical Trial
2009
NCT01277289
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Erydel | EryDel S.p.A

Active Ingredients

Drugs in Phase 3 Trials (2)

dexamethasone (3 trials)

urea (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 3)

Ataxia Telangiectasia (Phase 3)

Cerebellar Ataxia (Phase 3)

Crohn Disease (Phase 3)

Nervous System Diseases (Phase 3)

Telangiectasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2